Profile

Hospital Pharmacist engaged in research on refining EGFR-monoclonal antibody treatment in colorectal cancer at the Leiden University Medical Hospital (LUMC). Plays the piano, speed skates, travels the world and enjoys the good things in life.

Experience

Hospital Pharmacist

2015 - Present
Hospital Group Twente, Almelo/Hengelo

PhD Student

2009 - 2015
Leiden Univesity Medical Center, Leiden

Hospital Pharmacist in Training

2009 - 2014
Leiden Univesity Medical Center, Leiden

Pharmacist

2008 - 2009
Zuwe Hofpoort Ziekenhuis, Woerden

Publications

Sezgi B, Damhof MA, Faneyte IF, van der Palen J, Krens LL. Het gebruik van risicomedicatie voor maagulcera en maagbescherming in relatie tot het ontstaan van ulcera na een bariatrische ingreep. Nederlands Platform voor Farmaceutisch Onderzoek. 2017;2:a1650.
Baas JM, Krens LL, ten Tije AJ, Erdkamp F, van Wezel T, Morreau H, Gelderblom H, Guchelaar HJ. Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients. Invest New Drugs. 2015 Dec;33(6):1242-7.
Baas JM, Krens LL, Bos MM, Portielje JE, Batman E, van Wezel T, Morreau H, Guchelaar HJ, Gelderblom H. Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients. Anticancer Drugs. 2015 Sep;26(8):872-7.
Krens LL, Simkens LH, Baas JM, Koomen ER, Gelderblom H, Punt CJ, Guchelaar HJ. Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study. PLoS One. 2014 Nov 6;9(11):e112201.
Krens LL, Pablo-Baak R, Mommersteeg MM, Hilhorst M, Ruijtenbeek R, Guchelaar HJ, Van der Straaten, T. Abstract 1846: Co-treatment with simvastatin and cetuximab in KRAS mutant LoVo cells decreases PTK activity effectively and increases STK activity to overcome the anti-EGFR resistance Cancer Res October 1 2014 (74) (19 Supplement) 1846.
Krens LL, Baas JM, Verboom MC, Paintaud G, Desvignes C, Guchelaar HJ, Gelderblom H. Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction. Chemother Pharmacol. 2014 Jun;73(6):1303-6.
Krens LL, Baas JM, de Jong FA, Guchelaar HJ, Gelderblom H. Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report. Cancer Chemother Pharmacol. 2014 Feb;73(2):429-33.
Krens LL, Baas JM, de Jong FA, Guchelaar HJ, Gelderblom H. Pharmacokinetics (PK) of panitumumab in a single patient with metastatic colorectal cancer (mCRC) and liver dysfunction. Journal of Clinical Oncology 31, no. 4_suppl (February 2013) 594-594.
Baas JM, Krens LL, Guchelaar HJ, Ouwerkerk J, de Jong FA, Lavrijsen AP, Gelderblom H. Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review. Cancer Treat Rev. 2012 Aug;38(5):505-14.
Baas JM, Krens LL, Guchelaar HJ, Morreau H, Gelderblom H. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist. 2011;16(9):1239-49.
Krens LL, Baas JM, Gelderblom H, Guchelaar HJ. Therapeutic modulation of k-ras signaling in colorectal cancer. Drug Discov Today. 2010 Jul;15(13-14):502-16
Swen JJ, Krens LL, ten Brink MH. Een uur leven kost maximaal 9 euro 13. NRC Next, 2010 February 15, opinion section: 18 -19 (article in Dutch).